Synaffix and Mitsubishi Tanabe Pharma Sign License Agreement for ADC Technology
Published on 08/07/2025 at 18:06 | prnewswire.co.uk
License agreement centered around development of a single ADC programUsage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagementView original content:https://www.prnewswire.co.uk/news-releases/synaffix-and-mitsubishi-tanabe-pharma-sign-license-agreement-for-adc-technology-302346918.html
en | boerse | 67955869 |
